Receptor activator of nuclear factor kappa-B ligand–Receptor activator of nuclear factor kappa-B–Osteoprotegerin signaling axis (RANKL–RANK–OPG axis)

The Receptor activator of nuclear factor kappa-B ligand (RANKL)–Receptor activator of nuclear factor kappa-B (RANK)–Osteoprotegerin (OPG) signaling axis is the central regulator of bone metabolism and osteoclast development (PMID: 11242091). RANKL (TNFSF11) is a cytokine produced by osteoblasts and osteocytes that binds to its cognate receptor RANK (TNFRSF11A) on osteoclast precursors, stimulating their differentiation into mature, bone-resorbing cells (UniProt O14788, Q9Y6Q6). OPG (TNFRSF11B) acts as a soluble decoy receptor that competitively binds to RANKL, thereby neutralizing its activity and maintaining bone homeostasis (UniProt O00300). Dysregulation of this axis, often characterized by an elevated RANKL/OPG ratio, is a hallmark of skeletal diseases such as osteoporosis, Paget's disease, and bone destruction associated with malignancy (PMID: 30104444). Beyond bone, this axis plays significant roles in the immune system, including lymph node organogenesis and T-cell-dendritic cell communication (PMID: 12750175). Therapeutic intervention targeting this axis, most notably with the monoclonal antibody denosumab, effectively inhibits RANKL to reduce bone resorption and increase bone mineral density (PMID: 19671655). Clinical applications include the treatment of postmenopausal osteoporosis, prevention of skeletal-related events in patients with bone metastases, and management of giant cell tumor of bone (PMID: 20970321).

Other names

RANK/RANKL/OPG pathwayTNFSF11/TNFRSF11A/TNFRSF11B axisOsteoprotegerin/RANKL/RANK systemRANKL-RANK signaling pathway

Inhibition of RANKL prevents its binding to the RANK receptor on the surface of osteoclast precursors, thereby suppressing osteoclast formation, function, and survival to reduce bone resorption and increase bone mineral density (PMID: 19671655).